Episodes / Mushrooms for the Mind & Immune System | Paul Stamets /
Full transcript
Mushrooms for the Mind & Immune System | Paul Stamets · 2:28:55 · 2388 segments · transcribed with distil-large-v3 on Nov 17, 2026. Timestamps open the source at that second.
-
It was extraordinary.
-
I refused to be an apologist for my interest in psilocybin.
-
And now it's a revolution, sweeping the planet.
-
There's a revolution from the underground.
-
2.5% of Americans admitted they use psilocybin.
-
last year. Microdosing or macrodosing? Both. That's over 8 million on my calculation
-
Americans. Do you think this is because of the studies on repeated use of psilocybin as beneficial
-
for major depression? Yes. Yes. The clinical trials. For people who are depressed, PTSD,
-
all sorts of other. And then increasingly, there is evidence that psilocybin increases
-
neuroplasticity and creates new neural networks.
-
And that's the area we have focused a lot of attention on.
-
I'm with a research group, and we're very excited about what we're seeing.
-
Other scientists are now also showing the same thing.
-
The observational studies, and this is easily discoverable,
-
anybody wants to search the web for this,
-
specifically significant association of an deduction of crime
-
with a person who's done one dose of celltobin,
-
partner-to-partner violence,
-
two heroic doses of cellocybin, 90% of people addicted to tobacco compared to the nicotine patch, one year later, we're not smoking.
-
So we define heroic dose?
-
Let me define it in several ways.
-
For those of you who know what psilocybe capensis, the golden tops, that's the most commonly cultivated mushroom, psilocybin mushroom in the world, super easy to cultivate.
-
That typically is over two and a half grams.
-
Really, the hero's journey is around four to five grams.
-
This is where you have set in setting,
-
and it's so important you have therapy afterwards.
-
It's so important that people don't do it.
-
Would you say before, during, and afterward?
-
Preparatory is really important,
-
so you don't have to understand
-
what you're going to experience.
-
There's a great nonprofit in Canada called Roots to Thrive.
-
Dr. Pamela Criscoe is one of the co-founders of it.
-
They really have a lot of experience with end of life
-
permitted by the Canadian government,
-
you know, on a case-by-case basis.
-
Yeah, we should probably, before we continue,
-
forgive me for interoperative. We should touch on legality and we should touch on categories of
-
humans for which there's could be elevated risk. So as far as I know, as far as I know,
-
psilocybin has been decriminalized in the United States in a few places, but is still,
-
I have to pronounce this very clearly illegal to possess or sell. That's my understanding.
-
Absolutely. Very important. And you cross, you know, state lines. You're involved in interstate
-
transportation of a Schedule I drug.
-
Possession of it is federally illegal.
-
Transportation across state lines is very federally illegal.
-
So Oregon and Colorado have decriminalized.
-
I've spoken in front of two city councils in Washington State
-
and unanimity of the city councils to decriminalize the possession of
-
cell asylum to the lowest priority of law enforcement.
-
This is one of the few times I'm going to say, lawyers,
-
what a great idea you came up with.
-
They made less of a violation than a parking ticket.
-
So they decriminalize it.
-
Didn't legalize it.
-
So Olympia, Seattle, Mount Vernon, Port Townsend.
-
All the places with a lot of trees, Oregon, Colorado.
-
What about categories of risk?
-
So my understanding of the literature is that people who have a genetic or, let's just say, familial or other predisposition to psychosis or bipolar disorder need to be very, very careful.
-
This is very, very serious.
-
They need to be pre-screened.
-
They need to, we need to have adults in the room on this.
-
This is not a party drug.
-
This is a serious medicine.
-
70% of people typically have a positive experience.
-
The Compass Sulocybin studies are showing about 40%, 45% resolution of treatment-resistant
-
depression or major depressive disorder.
-
I don't remember which.
-
But it's clearly a very powerful medicine.
-
Doesn't it work for everyone?
-
Very interestingly, Johns Hopkins, Roland Griffiths, who unfortunately passed away,
-
he had already led the charge on this.
-
They had a retro-respective study 14 months after heroic doses of psilocybin.
-
They interviewed the individuals, and as I remember, about 70% of the individuals described it as an extremely positive experience in the top five positive experiences of our life.
-
30% of the people described it as a difficult experience.
-
But the 70% of the people, 14 months later, they determined the act of re-remembering this experience was psychologically beneficial.
-
They relive the experience.
-
Well, that's reliving a neural pathway and a memory.
-
The 30% of the people had a difficult experience,
-
there was no adverse effects post the experience, 14 months later.
-
They just said, not for me.
-
I'm not going to do that again.
-
That was too difficult.
-
So people have schizophrenia, psychosis, absolutely.
-
This is truly a mind-bender.
-
But that so many people can benefit from this.
-
And people need to realize this is the end.
-
anti-addictive drug. So many people, when they take a high dose of psilocybin, they look at the
-
mushrooms the next day and they say, no way, I'm not touching those. Many people use it one time in
-
their life, one time. Think of that. This is why for opioid use disorder, for tobacco, for alcoholism,
-
for all these addictive, for obsessive compulsive disorder, which is what we're involved in right now,
-
this seems to reprogram
-
not only the neuroescape
-
but we know there's dandritic tips
-
of being formed from the tips of the axons
-
and when these dendritic
-
spines grow out
-
and the adjacent axons
-
and they touch each other, you have synaptogenesis
-
and then you have neuroplasticity of a new neural pathway
-
in order to be able to think.
-
You have another way of breaking your addictive behavior
-
because you're not stuck in a rot.
-
And that's what so exciting is the neuroplasticity benefits of psilocybin.
-
Everything we're doing right now, Andrew, is related to the health of our nervous system,
-
our seeing, or listening, or allocuting, me trying to formulate thoughts.
-
It's all based on the health of our nervous system.
-
I think psilocybin will go down as a paradigm shifting drug rediscovered
-
that could have the most dramatic impact for the health of individuals
-
and society of any medicine discovered in history.
-
That's what I believe.
-
That's a big statement.
-
I spent some time with the clinical trials on psilocybin for major depression, a little bit
-
on the data for OCD.
-
And I should just point out, we're not talking about OCD of that this person is really
-
nitpicky, quote-unquote, anal retent.
-
We're talking about people whose compulsive behavior is actually strengthened the obsessions,
-
and that's a vicious loop.
-
It's very, very detrimental to everyday living.
-
So if these things can provide relief, and the clinical trials are very encouraging,
-
I'm on board.
-
I do have a question.
-
I just would like your thoughts.
-
As you point out mechanistically, we know that psilocybin can create new neuronal connections
-
in the brain, maybe unmask existing connections as well, from what I understand.
-
I've been intrigued by the sort of paradox where plasticity is great, but the directing the plasticity
-
toward a particular endpoint, the resolution of the depression, of the obsessions, of the excessive
-
ruminations.
-
I mean, that's sort of the goal, right?
-
It's not plasticity.
-
It's directed plasticity.
-
And there I feel like that the qualified therapy plays a critical role, right?
-
It's not clear that people can just kind of freestyle this.
-
And so I think that for me, the big question in the psychedelic therapy's realm is the experience of the psychedelic, like the thoughts, the, they're unusual, you know, compared to everyday life.
-
Are the thoughts, are the, is the therapy, is what we say and what we hear, what we think and what we feel during those psychedelic sessions.
-
is that critical to the clinical outcome?
-
Because ultimately, there's also a lot of neurochemistry happening that facilitates plasticity.
-
So maybe we don't care about separating those two.
-
But I think if people are going to use these powerful compounds to try and be healthier,
-
I think it's going to be really important to figure out what should they be asked during these sessions.
-
I don't think any of that is standardized.
-
Like we can say more about dosage and strain than we can about what a good psychedelic therapy should look like.
-
Absolutely.
-
It's so important.
-
Let me just bring it back from my perspective.
-
My father, who was a pro-Nixon anti-drug guy in his 70s,
-
it said, Paul, how I'm going to do Sulzheimer's with you?
-
How old was he when he said that?
-
What, 74?
-
All right, call up your parents, folks, you know, I'm just kidding.
-
It's like, I was blown away.